Entera Bio Ltd.
NasdaqCM ENTX
Entera Bio Ltd. EBIT Margin for the year ending December 31, 2023
-
Entera Bio Ltd. EBIT Margin for the year ending December 31, 2022 was -9,652.24%, a -351.13% change year over year.
-
Entera Bio Ltd. EBIT Margin for the year ending December 31, 2021 was -2,139.58%, a 30.07% change year over year.
-
Entera Bio Ltd. EBIT Margin for the year ending December 31, 2020 was -3,059.73%, a 37.66% change year over year.
-
Entera Bio Ltd. EBIT Margin for the year ending December 31, 2019 was -4,908.47%, a -125.97% change year over year.
| Date | EBIT Margin | EPS (Basic) | EPS (Diluted) | Shares (Basic, Weighted) |
|---|
| CEO | Ms. Miranda J. Toledano M.B.A. |
| IPO Date | June 28, 2018 |
| Location | Israel |
| Headquarters | Kiryat Hadassah Minrav Building |
| Employees | 17 |
| Sector | Health Care |
| Industries | |
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
Past 5 years
USD 1.05
USD 3.31
USD 2.03
USD 1.93
StockViz Staff
January 15, 2025
Any question? Send us an email